S
SkylineDx
Molecular diagnostic tests for oncology and inflammatory diseases
About SkylineDx
SkylineDx is a biotechnology company focused on developing molecular diagnostic tests for oncology and inflammatory diseases. The company was established in 2013 as a restart of the former Skyline Diagnostics, with Dharminder Chahal as a founder and the current CEO. Headquartered in Rotterdam, the Netherlands, SkylineDx also operates a CAP/CLIA certified laboratory in San Diego, California.
The company's business model is centered on bridging the gap between academically discovered gene expression signatures and commercially available diagnostic products. It collaborates with medical centers to develop and validate biomarker discoveries, then partners with commercial entities to market and sell the resulting diagnostic assays globally. A key product is the Merlin™ Test for melanoma, which uses a proprietary algorithm to analyze a patient's gene expression profile along with clinical factors to predict the risk of nodal metastasis. This test helps physicians identify which early-stage melanoma patients can safely avoid an invasive sentinel lymph node biopsy procedure. Another significant product is the MMprofiler for Multiple Myeloma, which predicts a patient's risk profile to assist in treatment planning.
SkylineDx serves healthcare professionals by providing them with tools to personalize treatment based on a patient's individual disease profile. Revenue is generated through the sale and commercialization of these diagnostic tests and kits, with a focus on securing reimbursement and market access. The company has established partnerships with institutions like the Mayo Clinic and Tempus to advance the clinical utility and accessibility of its tests.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Rotterdam, Netherlands
- Employees
- 92
- Open positions
- 2
- Dealroom signal
- 56.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Molecular Biology, Health Diagnostics, Spinout, Biotech and Pharma, Horizon Europe, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| OtherOther financing | Dec 2021 | $0 | — | Van Herk Investments | — |
| EARLY VC✓Equity / VC | Sep 2019 | $22M | $88M | Van Herk Investments | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for SkylineDx is 5.7K monthly website visits, up 67.6% over the last three months. SkylineDx's team grew 22.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- HIHorizon 2020 FTI (Fast Track to Innovation)
Series A1 investor entered at this stage
Van Herk Investments
Other known investors5 additional known investors
Amsterdam UMC
University of Amsterdam
Amsterdam Academic Ventures
Utrecht Holdings
UvA - AMC - HvA Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SkylineDx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SkylineDx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.